What happened yesterday was more disturbing than 3/30? Almost everyone thought Du would rule in Amarin’s favor. That was a sleepless night - right up there with 10/16/2013. Yesterday was expected - maybe not that quickly, but the odds of prevailing were nothing like those going into Du’s debacle.
So, I’m reflecting on the time since 10/2013 and the near death rattle we were hearing at 78 cents a share as we waited for interim looks to give us hope that an early stop would bring salvation. And time went on, until finally 9/24 arrived and the benefits of Vascepa were proven to the WORLD. That’s Amarin’s story!
This is a significant setback, no doubt. But if you look at the opportunities outside the US, the future is great. It’s been a long road and the jack wagons in the court system just ran Amarin into the ditch - but they will make adjustments and get back on the road and finish the trip. It’s tough right now seeing companies like Tesla and Apple creating tremendous value for their shareholders - while we sit and wait.
BB has complained frequently about the analysts not covering EU in their valuations. Now, they don’t have much choice. I don’t know if an apples to apples comparison is possible between the US and EU markets, but it seems that the potential patient population in the EU is greater than the US, so why wouldn’t the potential revenue be at least as good as the US if not greater? And if these analysts have had average PTs of around $31 while ignoring EU and the ROW, then something is amiss! So, I’m watching and waiting for more sharp pencils to start working on their new valuations.
Dog needs to take a whiz.
